FERNDALE, Mich. and PETALUMA, Calif., July 27, 2011 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced a multi-year licensing agreement with Eloquest Healthcare, a wholly owned subsidiary of Ferndale Pharma Group, Inc., to market multiple Microcyn®-based products in the United States under the Eloquest Healthcare brand, including Oculus’ negative-pressure wound therapy solution and prescription wound care line. Negative pressure wound therapy is a therapeutic technique used to promote healing in acute or chronic wounds.
